

#### **Important Disclaimer**



This presentation has been prepared by Calix Limited (ABN 36 117 372 540) ("Company").

#### SLIMMARY INFORMATION

This presentation contains summary information about the Company and its subsidiaries ("Calix") and their activities current as at 23<sup>rd</sup> August, 2022. The information in this presentation is a general background and does not purport to be complete.

#### NOT FINANCIAL PRODUCT ADVICE

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. This presentation is not financial product or investment advice, a recommendation to acquire Calix securities or accounting, legal or tax advice. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Calix is not licensed to provide financial product advice in respect of Calix securities. Cooling off rights do not apply to the acquisition of Calix securities.

#### **FINANCIAL DATA**

All dollar values are in Australian dollars (\$ or A\$) and financial data is presented as at or for the full financial year ended 30 June 2021, unless stated otherwise.

#### **PAST PERFORMANCE**

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future financial performance or condition. Investors should note that past performance, including past share price performance, of Calix cannot be relied upon as an indicator of (and provides no guidance as to) future Calix performance including future share price performance.

#### **FUTURE PERFORMANCE**

This presentation contains certain "forward-looking statements". The words "expect", "future", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forwardlooking statements, including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Such forward-looking statements are by their nature subject to significant uncertainties and contingencies and are based on a number of estimates and assumptions that are subject to change (and in many cases are outside the control of Calix and its directors) which may cause the actual results or performance of Calix to be materially different from any future results or performance expressed or implied by such forward-looking statements. The forward-looking statements should not be relied on as an indication of future value or for any other purpose.. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. The forward-looking statements in this presentation speak only as of the date of this presentation. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forwardlooking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of Calix since the date of this presentation.

performance of Calix, nor does it guarantee the repayment of capital from Calix or any particular tax treatment. Persons should have regard to the risks outlined in this presentation and appendices.

#### **NOT AN OFFER**

This presentation is not and should not be considered an offer or an invitation to acquire Calix securities or any other financial products and does not and will not form any part of any contract for the acquisition of Calix securities.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any 'U.S. person' (as defined in Regulation S under the U.S. Securities Act ("U.S. Person")). The new shares to be offered and sold in the placement ("Offer") have not been, and none of them will be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. In addition, Calix has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended (the "U.S. Investment Company Act") in reliance on the exception from the definition of "investment company" provided by Section 3(c)(7) thereof. The New Shares to be offered and sold in the Offer may not be offered and sold to, directly or indirectly, any person in the United States or any person that is, or is acting for the account or benefit of, a U.S. Person except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws and pursuant to an exception from the registration requirements of the U.S. Investment Company Act provided by Section 3(c)(7) thereof. This presentation may not be distributed or released in the United States or to any U.S Person. The distribution of this presentation in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. Offers in Australia of the shares are only being made to persons who are "sophisticated investors" or "professional investors" (within the meaning of section 708(8) and section 708(11) of the Australian Corporations Act (Act) respectively) or otherwise pursuant to one or more exemptions under Section 708 of the Act so that it is lawful to offer the shares in Australia without disclosure to investors u

#### **NO ADVICE**

None of Calix's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorised, permitted or caused the issue, submission, dispatch or provision of this presentation and none of them makes or purports to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of them. For the avoidance of doubt, the advisers and their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents have not made or purported to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of them. To the maximum extent permitted by law, Calix and its advisers and their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, for any expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and the information in this presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Calix and its advisers and their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied. as to the currency, accuracy, reliability or completeness of information in this presentation and Calix's advisers and its affiliates, related bodies corporate, directors, officers, partners, employees and agents, take no responsibility for any part of this presentation or the Offer. Calix and Calix's advisers and their affiliates, related bodies corporate, directors, officers, partners, employees and agents make no recommendations as to whether you or your related parties should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and you represent, warrant and agree that you have not relied on any statements made by any of them in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them. Statements made in this presentation are made only as the date of this presentation. The information in this presentation remains subject to change without notice. Calix reserves the right to withdraw the Offer or vary the timetable for the Offer without notice.

#### INIVESTMENT DISK

An investment in Calix securities is subject to investment and other known and unknown risks, some of which are beyond the control of Calix, including possible delays in repayment and loss of income and principal invested. Calix does not guarantee any particular rate of return or the





# Sustainability is in our DNA

Mission: Delivering on our promises.



#### **FY22 ACHIEVEMENTS**

- First Sustainability Report (COP Communication on Progress) published in Nov 2021.
- SDG Ambition Acceleration Program (6 months) completed.
- Awareness training on the Sustainable Development Goals conducted for all ANZ, SEA, US and EU employees.
- Strategic SDG prioritization (using the "SDG Ambition Benchmarks" as defined by the UN):
  - 1. Science-based emissions reduction in line with the 1.5°C pathway
  - 2. Zero incidents of bribery and corruption
  - 3. Diversity across all levels of management
  - 4. 100% sustainability material inputs that are renewable, recyclable or reusable.
- CSR, giving back to the community:

Calix has become a Silver partner of WaterAid, in recognition of our leadership and continued support. Calix continues to support Ocean Impact Organisation and the Bacchus Marsh Women Football Club.


#### **FY23 COMMITMENTS**

- UNGC commitment and CEO support renewed; Second COP report to be submitted before end of November 2022.
- Integration of the SDGs into Line of business strategy to continue developing our technology with purpose.
- The Sustainability Team will work with Pangolin Associates to develop a roadmap to match or exceed the benchmark's level of ambition on reducing CO<sub>2</sub> footprint in line with the Paris Agreement. We are committed to:
  - 1. Measure footprint and risks
  - 2. Create targets
  - 3. Reduce footprint
  - 4. Communicate and lead

#### Calix is developing multiple environmental business opportunities...




..and looking to fast-track commercialisation and value-adding through JV / Licensing and Spin-Out strategies



CARBONDIRECT

#### Calix's core technology platform

A PATENTED PLATFORM TECHNOLOGY WITH THREE KEY FEATURES



Highly porous "honeycomb" structure = more chemical- and/or bio-activity









A new way to "heat stuff up"



28 patent families covering core technology and applications




>A\$120m has been invested to date in developing the technology.



#### **Key Highlights – FY22**



SIGNIFICANT PROGRESS ACROSS MULTIPLE LINES OF BUSINESS, "LOOK THROUGH" VALUE ACHIEVED FOR CO<sub>2</sub> MITIGATION TECHNOLOGY



#### **Investing for growth**

Employed 10 engineers,
1 finance and business development
and 6 R&D FTEs

Invested \$7.0m on capital items to enhance and accelerate our technology development

Invested \$1.8m on external commercial / advisory / legal / tax to advance our commercialisation along multiple business lines and geographies

. . . . . . . . . .

#### **FY22** priorities...and Report Card



**Behind** 





#### Water



CO, **Mitigation** 



**Biotech** 



**Advanced Batteries** 



#### **Sustainable Processing**

#### **Revenue and Gross Margin** growth via...

#### **US: At least**

- 1 new plant
- 1 major new US state entry

#### Successful test campaign conclusion - LEILAC-1

**Cement and Lime** 

Successful FID -



"full-scale" application



 Convert at least two MTA partners MOU's to full project / license agreements -

# **Marine Coatings**

APVMA approval


• 2<sup>nd</sup> license agreement

**Crop Protection** 

Successful initial trials with

#### Next new biotech application...health / pharma

Successful in-vitro study



Initial positive pouch cell results

Scale-up production trials – cathode materials

First battery module – commercial format

#### Refractories

 Convert MOU to full Project or License agreement

#### Spodumene

- Successful feasibility study
- Convert MOU to full Project or License MOU

#### **Develop next new sustainable** processing application

 ZESTY – iron and steel decarbonisation development underway

#### EU:

- First partner agreement
- Convert paid

trials to customers

• 1 new plant



#### Asia:

 Re-establish Chinese AQUA-Cal+ sales






**Look-through valuation achieved – Carbon Direct** investment into the LEILAC Group








**FY22 Financial Results** 

#### **Progress in FY22**

#### **EVOLUTION OF REVENUE PROFILE**





#### Key takeaways...

Sales in FY22 impacted by loss of low margin refined coal customer anticipated in acquisition valuation – offset by higher margin sales with gross profit increases

Fluctuations in grant income relates to timing of spend profile on our projects. Almost \$3m received in FY22 but deferred – further 12 announced grant funded projects secured over the last 12 months, whose income will be recognised over the life of those projects

As our "aggregated turnover" exceeded \$20m, we cannot claim the R&D cash rebate – which averaged \$5m over the previous 4 years. In place of this rebate, we earn accelerated tax credits instead

Sales revenues will include contributions beyond Water in FY 22/23 with paid studies for customers in Leilac and SusPro

## **Summary of Results FY22 – Profit & Loss Highlights**



INVESTING HEAVILY IN CAPABILITY TO CAPITALISE ON TECHNOLOGY COMMERCIALISATION

	FY22 (\$m's)	FY21 (\$m's)	Comments
Sales revenue	18.5	19.2	
Gross Profit	5.2	5.0	Focus on higher margin sales
Grant and other income recognised	2.3	5.2	Leilac 1 to Leilac 2 transition
R&D tax incentive	-	5.4	Tax rebate to tax incentive
Total revenue	20.8	29.8	
Sales & Marketing expenses	7.7	5.9	Investing in commercialisation
R&D	7.1	7.1	
Admin	4.9	2.6	Includes non-recurring expenses, mainly LEILAC Group deal
Operating Profit	(12.1)	0	

#### **Balance Sheet strength**



#### BALANCE SHEET STRENGTHENED THROUGH STRATEGIC SELL DOWN IN ONE OF OUR LINES OF BUSINESS

	30 June 22 (\$m's)	30 June 21 (\$m's)	
Cash & Cash equivalents	25.0	15.1	
Total Assets	61.2	51.6	
Total Liabilities	16.4	13.5	
Net Assets/Total Equity	44.8	38.1	
Excluding deferred revenue			
Current assets	31.6	27.0	
Current liabilities	5.8	5.2	
Net surplus of current assets over current liabilities [ex deferred revenue]	25.8	21.8	
Property, plant & equipment	18.7	14.5	
Intangible assets, including goodwill	10.1	8.9	

#### **Key Take-aways...**

Sale of minor stake [~7%] in Calix's LEILAC Group demonstrated underlying value in the assets and technology platform the Company has built.

Carbon Direct investment approach is an example of the flexible funding options that Calix has to accelerate and scale lines of business.

\$25.0m of cash on hand and minimal debt, providing financial and balance sheet flexibility.

#### **Progress in FY22**

# INVESTING IN TECHNOLOGY PLATFORM FOR MULTIPLE ENVIRONMENTAL OUTCOMES

Recent history demonstrates efficient use of capital driving material outcomes...


Since Calix's first commercial scale demonstrator plant came online in 2013, the Company has been diligently managing OPEX and CAPEX to grow the business and the technology platform.

Over those 9 years, the accumulated net operating cashflow was -\$1m, largely driven from successful grants, from which Calix has delivered significant outcomes

From a single application in wastewater treatment many years ago, this investment created a platform to launch opportunities in:

- CO<sub>2</sub> capture for lime & cement
- Decarbonization & electrification for multiple minerals processing applications
- Advanced battery materials, and
- Biotech applications

This fiscal prudence has given Calix a unique opportunity to grow multiple successful lines of business into large addressable markets.




### **Progress in FY22**

#### DETAILED ALLOCATION OF FUNDS BY LINE OF BUSINESS



		REVENUES	EXPENSES	САРЕХ	NET INVESTMENT	MARCH 21 CAP RAISE ALLOCATIONS	CARBON DIRECT INVESTMENT	WHAT DID WE ACHIEVE?
	Leilac	\$1.9m [\$2.8m grant cash received – but deferred]	(\$5.9m)	(\$5.1m)	(\$9.1m)	\$1.5m	\$24.5m	Carbon Direct investment – L2 to FID, 52 projects in the pipeline – new projects with Adbri & Boral - \$41m in additional grant funding for those 2 projects.
		\$1.4m	(\$3.5m)	(\$0.6m)	(\$2.7m)	\$1.0m		JV agreement with PLS – 45% share in 3ktpa Lithium Salt production plant – operational by 2025. \$20m in grant funding for the project with PLS. Zesty – pilot scale proof of concept at 2ktpa
<u>)</u>	<b>(</b> \$2)	\$0.4m	(\$2.4m)	(\$0.8m)	(\$2.8m)	\$4.5m		Pouch cell production and pilot scale manufacturing tested to 300kgs
3		\$0.1m	(\$1.5m)	-	(\$1.4m)	\$2.5m		APVMA approval for 1st insecticide label 2 <sup>nd</sup> license agreement in Europe
		\$16.9m	(\$11.8m) in COGS - 30.1% GP - (\$7.4m) in Opex	(\$1.0m)	(\$3.3m)	\$2.0m		Expanded margins across Water to 30.1% [up from 26%] positioned for growth in US at healthier margins [US margin at 33%]







# "Environment / Social / Governance" (ESG) Interest Continues to Strengthen



#### GLOBAL ECONOMIES, COMPANIES AND INVESTMENT FUNDS ARE ALL HEADING IN ONE DIRECTION



66% of global GDP\*
and carbon emissions currently
under net-zero commitments.
Source: Energy and Climate
Intelligence Unit



**Top companies committing to net-zero emissions**CAC 40, DOW 30, FTSE100 and
IBEX 35. Source: ECOACT



eschange Traded Funds
dramatically up again in 2021
US\$78b in assets allocated to ESG
funds in 2019 has grown to US\$391b
in 2021. Source: Statista



trillion per
year by 2030
Global investment capital
required to achieve
net zero outcome\*\*

From USD1.3 to USD4

<sup>\*</sup>Includes US – re-joined the Paris Accord in 2021 \*\*IEA World Energy Outlook 2021

# Calix's business opportunities and ESG tailwinds









#### **LEILAC Group: Scaling Up Calix's LEILAC Technology**


LEILAC-1 Belgium 2019 25,000 Tonnes / Year CO<sub>2</sub>



LEILAC-2 Hanover 2024 100,000 Tonnes / Year CO<sub>2</sub>



LEILAC-3
500,000 Tonnes / Year CO<sub>2</sub>



20 partners, including



















#### **LEILAC Group: A growing pipeline of projects...**

#### POTENTIAL LOWEST COST CEMENT AND LIME CO<sub>2</sub> MITIGATION SOLUTION

	Project Discussions	Initial Scoping	Detailed Scoping / MOU	Pre FEED / BOD	FEED	FID + Constructio n	Operationa 	Total
Aug 2021	21	7	4	1			1	34
Aug 2022	25	13	9	5 ADBRI BORAL  TARMAC		1 LEILAC-2	1 LEILAC-1	54

- Both Adbri and Boral have committed to net zero by 2050
- Both projects have commenced pre-FEED phase under project MOU's in parallel with commercial discussions regarding on-going use after demonstration
- Continue to look at risked equity
   / Build-Own-Operate-Transfer
   (BOOT) support to accelerate
   deployment







SEPT 2021: LEILAC-1 Output Report Released – Roadmap "2050" - Confirms LEILAC has potential to be lowest cost CO<sub>2</sub> capture technology for lime and cement

#### **Key Updates**

- Watch point COVID + Ukraine/Russia war has impacted supply chain / construction / people – budget and timeline
- Final Investment Decision milestone LEILAC2 taken. Flagpoints remain to address financial and technical watchpoints.
- 3 lime projects progressing well \$41m in government funding\* announced for Boral and Adbri projects in Australia, and Tarmac Buxton lime project proceeds to second round in UK BEIS decarb. projects

#### **Project Pipeline Movements**

- From February 2022 to June 2022, another 4 projects have come into the pipeline
- Progression of a number of projects through initial design and scoping work
- LEILAC-2 has passed FID and is in detailed engineering

#### **Sustainable Processing**

#### CALIX TECHNOLOGY ... EVERYWHERE!





**SPODUMENE** 

**Revolutionary at-mine low** CO<sub>2</sub> footprint Li salt manufacturing in Australia

MOU





REFRACTORY

CO, reduction into processes





existing magnesia production



Feasibility study proceeding under binding MOU terms. Pilot plant testing of full flowsheet has produced Li<sub>3</sub>PO<sub>4</sub> at specification for market testing. \$20mil in Australian government support announced

> World Bank modelling shows 500% growth of Lithium to 2050\*3

in May 2022

Successful pre-FEED. Industrial testing awaiting client plant trials. FEED study delayed whilst RHIM evaluate location options. Other Magnesium oxide projects under discussion

> 15 million tonnes \*2 per annum global addressable market

Successful initial testing with a range of Fe ore types. Planning well advanced for next phase of development testing and demonstration-scale plant

**IRON AND STEEL** 

New patent filed for

Calix's ZESTY process

Iron and steel is responsible for 7% of global CO<sub>2</sub> emissions\*6 – just behind cement and lime



LC3

**Next Generation Clay Cement** 



**ALUMINA** 

**Electrifying Aluminium** Oxide production

High electricity costs delaying projects in **Europe. Opportunities** elsewhere being reviewed

Potential Clay production to meet demand 1.1B Tonnes p.a. \*4

Strong industry interest in first trials scheduled for Q3/4 CY22

> Global Alumina production on steady growth past 125Mtpa in 2021 \*5

Environment and Energy Study Institute (2019)

<sup>\*2</sup> Based on RHIM being 15% of the global market (RHIM Annual Report 2020) <sup>73</sup> Forecasts indicate that Lithium is on a 500% growth curve by 2050 (World Bank 2017)

<sup>\*4</sup> Mining Industry worldwide statistics and facts (M. Garside 2021, Statista)

<sup>\*5</sup> Global aluminium oxide production survey, Statista 2021

<sup>\*6</sup> IEA – Iron and Steel Technology Roadmap https://www.iea.org/reports/iron-and-steel-technology-roadmap

#### **Development of lithium salt project with Pilbara Minerals**


#### TARGETING JV FORMATION AND COMPLETION OF FEED IN FY23







- PILBARA MINERALS (ASX:PLS): JV MOU Executed with \$20m in Federal Government funding announced under the Modern Manufacturing Initiative<sup>1</sup>
- Project CAPEX budget estimate from scoping study is \$50-70m
- CXL will own 45% of the JV and contribute 35% of the capital (10% free carry negotiated as per Calix IP contribution)
- Majority of world's lithium forecast to be sourced from hard rock lithium – projected to grow 5x in this decade<sup>2</sup>
- Global market Lithium Carbonate and equivalents: 0.54 MTpa in 2021; 3.3 MTpa by 2030<sup>3</sup>
- The demonstration plant will have 2 distinct advantages:
  - Low-carbon: solar-powered electrification of calcination
  - Recovery: Calix technology gives higher recovery from ore body
- At current lithium prices, the demonstration scale plant running at full capacity could generate ~US\$180m revenue for the JV<sup>4</sup> on an annual basis



#### **Next Steps**

JV established (Demo plant, joint marketing of technology) - target CY 2022 FID targeted H1 2023

Market development – lithium phosphate salt

Construction targeted from Q2 2023 to Q1 2024

Commissioning and testing during 2024, on way to achieving full production and sales, subject to market developing for lithium phosphate salt product

Li-salt production technology to then be licensed by the JV to Pilbara Minerals and the global spodumene industry

<sup>1.</sup> Grant funding announced, awaiting contract finalisation following change in Federal Government in May 2022

<sup>2.</sup> Benchmark Minerals Intelligence, Oct 2020


McKinsey Apr 2022

<sup>4.</sup> Calix share is projected to be 45% of the JV. JV total revenue Assumes prevailing lithium prices Li-Carbonate-equivalent of US60.5k/tonne (87k A\$/tonne) and targeted lithium phosphate production of ~3,000tpa (source: Argus metals 18 May 2022)

#### **ZESTY: Zero Emissions Steel Technology Development**

# () calix

#### SUCCESSFUL ACCELERATED DEVELOPMENT TO PILOT SCALE TESTING IN 6 MONTHS



#### Phase 1: Jan 2022 to Mar 2022

LAB Scale: H<sub>2</sub> reduction kinetics, Ore variability and performance. Kinetic theoretical work combined with Imperial College lab data

Reactor modelling based upon kinetics and known reactor performance from multiple other mineral fingerprinting runs

#### **ZESTY** potential theoretical confirmation

Conversion of Calix's Bacchus Marsh BATMn electric calciner facility to run hydrogen

#### Phase 2: April 2022 to June 2022 – PILOT Scale:

Conversion of Calix BATMn fully electric calciner to run iron ore feed / hydrogen atmosphere – completed in 4 weeks


**Confirmation of electric calciner + reduction performance** – various H<sub>2</sub> concentrations, ores, temp. profiles and flowrates

#### FIRST ORES PROCESSED SUCCESSFULLY

- Processing test runs of siderite produced complete conversion to metallic iron
- Processing of hematite produced very high conversion to metallic iron under increasingly lower **temperature** operation – further runs underway
- Processing of magnetite produced lower but reasonable conversion results optimisation runs being carried out

Next steps: further ore testing, commence basis-of-design for 30kTpa demonstration facility • • • • • • • • 22





Water

#### Water business – Magnesium Hydroxide Liquid "MHL" – a safe alkali chemical








#### Strategy:

**Aggressive growth** plan continues – Continue to Seed market in 2 new US states ...

- Still targeting 1 to 2 new hydration plants in CY2022
- Growth in 2 new states
- Focus on Caustic Industrial Segment and Odour Control Municipalities
- Complete Successful trial in Drinking
   Water
- Hire 3 new sales resources




#### **FY22 Updates:**

- Revenues US\$9.7m FY22 vs \$US11.4m FY21 down 15 % on prior period Key issue second half revenue is cessation of refined coal tax credits during H2 FY22 = no more MHL sales into refined coal (heavily weighted to H2).
- Tough conditions with 2 sales resources. 4 truck drivers and logistics support leaving.
- Despite these conditions Sales excluding refined coal were up 11% compared to H2 FY21 and 15% compared to Q4 FY21.
- Gross Margins was also up year on year FY22 to 33% vs FY21 27% - good trend continues. These higher margins enabled generation of higher gross profit despite lower reported sales.
- TX market entry continues run-rating at \$US500k+ sales, growing pipeline, plant location found and lease agreed, procurement underway

#### Water business – Magnesium Hydroxide Liquid "MHL" – a safe alkali chemical

AUS / NZ STEADY, SE GROWTH EXPERIENCING HEADWINDS...BUT PROGRESSING





#### **Strategy:**


- AUS/NZ **SHARE OF WALLET:** Focus on organic growth in key accounts industry leading monitoring & dosing solutions with ongoing service and maintenance.
- China **RE-ESTABLISH GROWTH:** COVID pressures continued in H2 FY22, but new channel to market agreement being progressed
- SEA **GROW:** Trial success leading to new partner agreements for Thailand, India
- EU **NEW MARKET ENTRY:** Under review given inflationary and freight pressures

#### FY22 Update:

- AUS/NZ/SEA Revenue FY22 \$3.4m vs \$3.5m in FY21 - slight decline 3% on prior period. Overall GM up to FY22 19% (FY21 17%) - despite significant increase in input (gas) prices.
- SEA positive new trial results in growth markets
   Thailand, China Quanzhou, China Tianjin
- EU COVID, cost increases (gas), raw material and sea freight impact has delayed establishment of EU business / plant. Market entry strategy under review.








**Advanced Batteries** 

#### Advanced Batteries – novel structured high power electrode materials

PILOT PRODUCTION ON TRACK, FIRST EV TEST APPLICATION EARLY 2023


#### LOWER COST, SIMPLE, SAFE CHEMISTRY

Approx. 6x **lower energy** route than conventional lithium manganese oxide (LMO) production, and is producing **strong**, **active** "hierarchical porous onion (HPO) structures in the tiny crystals..."




... we continue to develop and scale the process to further reduce the time and energy required for "product lithiation" = minimise the CO<sub>2</sub> footprint, and cost, of our cathode materials.

#### PROMISING PERFORMANCE



Specificenergy and power presented on a per unit weight of the cathode active material (CAM) basis
 All results are from half-cell electrochemical discharge rate screening tests with CAM loadings of 0.5 mAh/cm





\*full LMO | LTO coin cell, 1mAh/cm2 cathode loading

Very promising early test results! Novel "HPO" (Hierarchical Porous Onion) structure suited to high power (fast charging/discharging) applications.

#### **NOVEL STRUCTURE**

Early test results very promising





Structure of Calix HPO LMO is preserved with no observed decay in novel structure of Calix LMO following extended electrochemical cycling (high magnification, cross-sectional images of cathode foils)



# SCALE-UP UNDERWAY

Pilot line prototyping of Calix LMO pouch cells (30-50 test cells)

Q2 2022

Pilot production of Calix LMO (150-200 kg)

Q3 2022

300 kg



Pilot line production of Calix LMO pouch cells for 2.4kWh battery pack

Q3 2022 (

On Track

Integration and demonstration of pack in EV application

Q4 2022


Target Q1,











Biotech

#### Calix's biotech business...very high surface area magnesium oxide - "nano/bio-active"

#### GOOD PROGRESS ON ALL FRONTS: EARLY REVENUES + COMMERCIALISATION STEPS CONTINUE



#### **CROP PROTECTION**

#### **Proof-Of-Concept**

- 6th consecutive year of field trials
- broad spectrum anti-fungal & anti-pest efficacy
- Initial sales commenced FY21 0.07m
- Similar sales FY22 0.07m COVID impacts

#### **Market Value Drivers**

- reduced toxic pesticide use
- substitute for banned actives
- safe, sustainable

#### MARINE COATINGS

#### **Proof-Of-Concept**

- 26-month exposure trial completed -Bowen QLD - material efficacy vs control
- End-user trials at 18-month with 2 x coatings manufacturers and 1 major enduser; cold and tropical waters
- Phase 2 trials planned multiple formulations, 12 months

#### **Market Value Drivers**

- reduced expensive + toxic copper use
- safe, sustainable

#### ANTI-MICROBIALS

#### Proof-Of-Concept

- Calix materials supress anti-biotic resistant bacteria = "Superbugs"
- Initial 6-month program with QU "Centre for Super Bugs Solutions" positive outcome - efficacy
- Next stage trials in planning

#### **Market Value Drivers**

- pathogen suppression, not a biocide
- excellent safety profile
- low / limited antibiotic resistance
- safe, sustainable

#### **Latest Updates**

#### **Commercialisation: progress**

- Australia: label registration; ACHIEVED! APVMA (Australian Pesticides and Veterinary Medicines Authority)
- 2nd license ACHIEVED!!- EU distribution Profyto (https://www.profytodsd.nl/)
- 3rd license in negotiation

18 months' exposure – Williamstown, Vic – Successful 50% Cu Substitution



Test formulation 1.

- 50% of Cu substituted with bioactive MgO

In Market Formulation

#### Development pathway; Anti-Microbial Resistance (AMR); Academic & Industry Engagement

- 1. Queensland Uni. Centre for Super Bug Solutions;
- 6-month collaborative research agreement & program complete
- broad spectrum bactericidal activity on pathogenic bacteria
- low resistance development pathway confirmed
- efficacy equally apparent on drug susceptible & resistant strains
- 2. Australian Research Council (ARC) \$4.5m CEA-StAR program
- focus on AMR solutions in veterinary / livestock
- Calix invited to participate; 5-year fundamental research program
- 3. Cooperative Research Centre (CRC) \$34.5m SAAFE program
- focus on AMR in agriculture broadly; on farm crop, post harvest, live-stock
- Calix a partner, multi-year research program



#### **Calix's FY23 priorities...**

#### CONTINUED ACCELERATION - ESPECIALLY DECARBONISATION PROJECTS...



#### Water

Water Treatment

Aquaculture

#### US: At least

- 2 new plants
- A second major new USstate entry

EU / China:

Re-establish market entry



#### **Biotech**

**Crop Protection** 

**Marine Coatings** 

Health and Pharma

#### **Crop Protection**

• 3rd license agreement

#### **Marine Coatings**

 Successful phase 2 trials with MTA partners

# Next new biotech application...health / pharma

• Successful initial in-vivo studies



# Advanced Batteries

Advanced Cathode & Anode Materials

First battery module – commercial format

Basis of Design – demonstration facility for cathode production

At least 1 new chemistry = pouch cell success



# **Sustainable Processing**

Renewable-powered Mineral and Chemical Processing

#### Refractories

 Convert MOU to full Project or License agreement

#### Spodumene

- Full JV Agreement
- Successful FEED study leading to FID

#### **Iron and Steel**

- Successful expanded ore program
- Basis of Design: Demonstration facility






#### **LEILAC Group**

CO<sub>2</sub> Mitigation for Cement & Lime

- Convert at least two MOU's to full project / license agreements – "full-scale" application
- Convert at least 2 projects from BOD's to FEED studies
- LEILAC-2 long lead items procured, site works commenced

. . . . . . . . . .





**Board of Directors, Equity Structure** 

**Glossary** 

#### **Board of Directors**





Peter Turnbull, AM Non-Executive Chair



Helen Fisher
Non-Executive
Director



Jack Hamilton Non-Executive Director

Experienced Chair and Non-Executive Director with significant board and senior executive experience in the Australian and global resource, energy and technology commercialisation sectors.

Non-Executive Director of Karoon Energy Ltd. (ASX: KAR), Chair of medtech Auxita Pty Ltd, Chair of Airlie Energy, Chair of QADO Group/QADO Ventures and President of the Chartered Governance Institute (London).

Chair of Calix Remuneration and Nomination Committee, and Member of Audit and Risk Management Committee. CEO and Managing Director of Bio Capital Impact Fund (BCIF), a Non-Executive director and Chair of the Audit and Risk Management Committee of Paradigm Biopharmaceuticals Ltd (ASX:PAR) and Chair of the Victorian branch of AusBiotech.

Previously a partner of Deloitte for over 11 years, and led Deloitte's life sciences practice in Australia for 5 years, specialising in the financial services sector, with significant M&A transactions and strategic tax advice to publicly listed and large multinational companies.

Chair of Calix Audit and Risk Management Committee and member of the Rem and Nom Committee 30 years multidisciplinary experience in local and overseas energy industries, including as a Director of NWS Ventures (Woodside North-West Shelf project).

Currently a Non-Executive Director of Hazar Group (ASX:HZR). Previous Non-Executive Director positions include AnteoTech Ltd (ASX:ADO), Renu Energy (ASX:RNE) and DUET Group (ASX:DUE).

Chair of Calix Technology Committee, and member of Audit and Risk, and Rem and Nom Committees.



Phil Hodgson Managing Director & Chief Executive Officer



Dr Mark Sceats Executive Director And Chief Scientist

14 years of multidisciplinary experience with Shell, including as the General Manager and Alternate Director of its subsidiary Fuelink Pty Ltd, a \$700m revenue, 300-employee distribution and sales subsidiary.

7 years running a private consultancy providing strategy and M&A services across energy, food, infrastructure and water sectors.

Joined Calix in 2013 as CEO, became a Director in 2014 and is a member of Calix's Technology Committee.

Co-founder of Calix, and a member of Calix's Technology Committee.

Qualified physical chemist with over 52 years' experience, numerous academic roles, and numerous fellowships and recognitions.

CEO of the Australian Photonics CRC for 14 years.

Author of more than 165 academic papers in physical chemistry and inventor of 55 patented inventions.


. . . . . . . . . .

# Listed on the ASX in July, 2018

**ASX:CXL** 

# **O**calix

#### **Share Price Performance Since Listing**



Further Equity Detail	As at 23 August 2022
Free Float	161.6m shares
Employee Incentive Scheme Options	5.6m options

	As at 23 August 2022
Shares on issue	~161.6m
Share price on IPO	\$0.62 per share
Current Share price	\$6.60 per share
Market capitalisation	~\$1.07b

Major shareholders	As at 23 August 2022
Board & Management	14.5%
Australian Super Pty Ltd	8.2%
Nicholas Merriman and associates	6.8%
Paul Crowther and family	5.3%

# **Glossary**



Term	Meaning
Aluminium (AI)	Chemical element with the symbol Al
Anode	The negative electrode of a battery
APVMA	Australian Pesticides and Veterinary Medicines Authority
BATMn	Calix's core kiln technology – electrified – for battery and catalyst materials production
C, 2C, 4C, D	Charge rate, 1 C = charge in 1 hour, 2C charge in 30 min, 4C charge in 15 min etc. D is discharge – same metrics
Calcium (Ca)	Chemical element with the symbol Ca
Carbonation	The capture of carbon dioxide by contacting with lime (calcium oxide), to form limestone (calcium carbonate)
Cathode	The positive electrode of a battery
CCS	Carbon Capture and Storage
ccus	Carbon Capture, Utilisation and Storage
CO <sub>2</sub>	Carbon Dioxide
Copper (Cu)	Chemical element with the symbol Cu
EBITDA	Earnings Before Interest, Tax, Depreciation and Amortisation
Electrode	The material that stores the lithium ions in a charged (anode) or discharged (cathode) state in a lithium ion battery
Electrolyte	The medium that allows ions to move between the battery electrodes, via the separator
ESG	Environment, Social and Governance considerations
FID	Final Investment Decision
Fines	Small particles, which are usually very difficult to handle in kilns etc as they simply get blown out
Green Hydrogen	Hydrogen that is produced from and electrolyser using renewable energy
НВІ	Hot Briquetted Iron — "bricks" of relatively high purity iron ready for steel-making
НРО	"Hierarchical Porous Onion" - a crystal structure of lithium manganese oxide resembling tiny onion layers – allowing both strength and easier passage of lithium ions

34

# **Glossary**



Term	Meaning
Iron	The chemical element, represent by "Fe" on the periodic table
Iron Ore	Iron oxide mixed with various other minerals, as mined and "pre-processed" (purified) as best as possible
LFP	Lithium Iron Phosphate – a battery cathode material
LMO	Lithium Manganese Oxide – a battery cathode material
Lithium (Li)	Chemical element with the symbol Li
Lithium Concentrate / Lithium Salt / "Mid-Stream" Lithium	A form of lithium that is high in lithium content, to be shipped and utilised by battery producers
Lithium ion	The ionic form of lithium (Li+) – a positively charged atom of lithium
<b>LTO</b>	Lithium Titanium Oxide – a battery anode material
LEILAC	Calix's core kiln technology for Low Emissions Intensity Lime and Cement production with CO <sub>2</sub> capture
Manganese Carbonate (MnCO <sub>3</sub> )	Form of manganese used mainly in agriculture as a fertiliser supplement
Magnesium (Mg)	Chemical element with the symbol Mg
Manganese (Mn)	Chemical element with the symbol Mn
Metallurgical Coal	Very high carbon coal
MgO	Magnesium Oxide
MHL	Magnesium Hydroxide Liquid

# **Glossary**



Term	Meaning
Nickel (Ni)	Chemical element with the symbol Ni
NCA	A battery cathode material made from nickel, aluminium and cobalt
NCM, or NMC	A battery cathode material made from nickel, manganese and cobalt
Pelletisation	The formation of pellets from finer materials to aid in handling
Potassium (K)	Chemical element with the symbol K
Separator	The barrier between the anode and the cathode that prevents them touching, inside the battery
Sodium (Na)	Chemical element with the symbol Na
Spodumene	A high lithium-containing ore, and the source of the majority of the world's lithium supply
α-Spodumene	A tight Li-crystal formation, from which extraction of Li is difficult
β-Spodumene	A loose Li-crystal formation, from which extraction of Li is much easier than the alpha-form
Reduce / Reduction	The process by which oxygen is removed
Reductant	A material that, through its chemical properties, carries out reduction
Sponge Iron	Iron Ore that has been reduced (had the oxygen removed)
Steel	Mainly iron, with some carbon and other trace metals such as nickel, manganese etc depending upon the grade of steel being made
Sulphur (S)	Chemical element with the symbol S
Тра	Tonnes per annum
Wh / kWh	Watt-hours / kilowatt-hours - a measure of energy

# only sonal use

# Because there's only one Earth...



# ... Mars is for quitters

#### **Phil Hodgson**

Managing Director & CEO phodgson@calix.global +61 2 8199 7400

#### **Darren Charles**

CFO & Company Secretary dcharles@calix.global +61 2 8199 7400

#### **Simon Hinsley**

Investor Relations simon@nwrcommunications.com.au +61 401 809 653

